- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Business Brief
IBA teams with maker of novel PET agent
IBA teams with maker of novel PET agent
Ion Beam Applications and NeuroSurvival Technologies will work together to distribute, as well as optimize the radiochemistry of, NST's molecular imaging agent for apoptosis, the genetically controlled process of cell death associated with many diseases, including cancer. The agent, Aposense, will be distributed to sites participating in multicenter clinical trials to document whether the PET radiotracer incorporating fluorine-18 selectively targets and accumulates within cells undergoing apoptosis. IBA Molecular, a business unit of IBA, provides PET radiopharmaceuticals through a global network of radiopharmacies using 37 cyclotron-equipped manufacturing sites.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
